Molecular Cancer-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=1235519, encodeId=bd0712355198b, content=偏重的研究方向：肿瘤生物学 经验分享：这个杂志还能投吗，这个杂志申基金有用吗。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=02dc5450639, createdName=ms4000000217931705, createdTime=Fri Jul 29 18:09:48 CST 2022, time=2022-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=948961, encodeId=d42d948961b7, content=50天了， 还没外审， Editor Invited 和 Editor assigned切换了三轮， 是没有编辑在工作吗？ 太慢了！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKfLDy7CohNq1oaBp12SkJfcXibVV6T5p8zzicUBYPq49OibwhzZswbxnxiaZWSn5QnBGZE64UPzcE1ng/132, createdBy=f10c1934056, createdName=Dr.Yuki, createdTime=Wed Mar 17 11:47:52 CST 2021, time=2021-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1210365, encodeId=433c1210365b7, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：caner 经验分享：最新发表的这两篇国人的综述挺不错的。一篇PROTAC。一篇CRISPR。Molecular Cancer靠综述拉动****无可厚非。一直不明白为啥要以国人论文百分比来评价一个期刊。愚蠢短浅自恨。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a3ed5633363, createdName=ms4000001729535049, createdTime=Mon Apr 11 20:32:55 CST 2022, time=2022-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1197474, encodeId=3f30119e474f1, content=偏重的研究方向：肿瘤 经验分享：molecular cancer杂志近年来尤其热门，深受国人喜爱。但一个杂志受广泛认可需要时间的沉淀，除了坚持发表高质量的论文外，还需要正确对待过去。许多pubpeer等上被揭露的发表在该杂志上的文章，不仅没有撤稿，而且连个订正都没有。在这点是，JECCR杂志就做的相对好点。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77772040306, createdName=1811e984f8m, createdTime=Sat Feb 26 13:02:50 CST 2022, time=2022-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1187896, encodeId=f392118e8961f, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤微环境 经验分享：我只能说这是一个接地气的杂志。相比较Nature Medicine, Cancer discovery, Cancer Cell等几个大多数人可望不可及的高端杂志而言。工作创新性一般并且工作量足够的话，Molecular Cancer是比较好的选择。给广大平庸的工作者提供了一个出口。相信以后也会成为Nature Medicine, Cancer discovery, Cancer Cell拒稿论文的备选杂志。至于说非编码环状RNA研究，确实跟风太厉害。真正有价值的不知道有多少。但是非编码确实有存在的重要意义。中科院的陈玲玲研究员就是专门做非编码，顶刊发了不少。中科院院士陈润生也是研究非编码RNA的。国自然也有众多非编码立项。只能说具体论文具体分析。大家擦亮眼睛。看看哪些CircRNA是沙子，哪些是黄金。做好自己的研究，把好自己论文的关。形成良性循环。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a3ed5633363, createdName=ms4000001729535049, createdTime=Tue Jan 25 06:35:02 CST 2022, time=2022-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=902691, encodeId=7f0990269109, content=editor assigned 两周了，还没动静！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=120, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c1c1677649, createdName=littleb, createdTime=Fri Nov 27 09:01:48 CST 2020, time=2020-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2183036, encodeId=e8f421830362e, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：投了一篇大综述，被nature cancer 拒下来的，审稿两个月给了小修, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad038147437, createdName=ms9000001581615796, createdTime=Sun Jan 21 19:51:36 CST 2024, time=2024-01-21, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2089546, encodeId=46a6208954658, content=偏重的研究方向：肿瘤;血管新生 经验分享：投稿三天，一直是editor appointed, 这个状态会持续多久呢，下一步会是什么🤔, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=172, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=af6a5287300, createdName=14856b50m82暂无昵称, createdTime=Wed Sep 21 14:58:39 CST 2022, time=2022-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2089863, encodeId=957d208986326, content=2天被拒, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f7f8116510, createdName=ms8000001299482728, createdTime=Thu Sep 22 23:55:42 CST 2022, time=2022-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813045, encodeId=51cc813045c7, content=明年能破20嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=138, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83er8t83BVhnMma2FlQbSibEIib2ESybuKEkLoRGMJUDXA68kp9iaicHOmWn7SjTx7hKcgqweO5VMahVLyQ/132, createdBy=8a1c2488674, createdName=franzjosef, createdTime=Tue Aug 25 15:07:36 CST 2020, time=2020-08-25, status=1, ipAttribution=)]

2022-07-29 ms4000000217931705

偏重的研究方向：肿瘤生物学
经验分享：这个杂志还能投吗，这个杂志申基金有用吗。

33 5

展开5条回复

[GetPortalCommentsPageByObjectIdResponse(id=1235519, encodeId=bd0712355198b, content=偏重的研究方向：肿瘤生物学 经验分享：这个杂志还能投吗，这个杂志申基金有用吗。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=02dc5450639, createdName=ms4000000217931705, createdTime=Fri Jul 29 18:09:48 CST 2022, time=2022-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=948961, encodeId=d42d948961b7, content=50天了， 还没外审， Editor Invited 和 Editor assigned切换了三轮， 是没有编辑在工作吗？ 太慢了！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKfLDy7CohNq1oaBp12SkJfcXibVV6T5p8zzicUBYPq49OibwhzZswbxnxiaZWSn5QnBGZE64UPzcE1ng/132, createdBy=f10c1934056, createdName=Dr.Yuki, createdTime=Wed Mar 17 11:47:52 CST 2021, time=2021-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1210365, encodeId=433c1210365b7, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：caner 经验分享：最新发表的这两篇国人的综述挺不错的。一篇PROTAC。一篇CRISPR。Molecular Cancer靠综述拉动****无可厚非。一直不明白为啥要以国人论文百分比来评价一个期刊。愚蠢短浅自恨。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a3ed5633363, createdName=ms4000001729535049, createdTime=Mon Apr 11 20:32:55 CST 2022, time=2022-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1197474, encodeId=3f30119e474f1, content=偏重的研究方向：肿瘤 经验分享：molecular cancer杂志近年来尤其热门，深受国人喜爱。但一个杂志受广泛认可需要时间的沉淀，除了坚持发表高质量的论文外，还需要正确对待过去。许多pubpeer等上被揭露的发表在该杂志上的文章，不仅没有撤稿，而且连个订正都没有。在这点是，JECCR杂志就做的相对好点。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77772040306, createdName=1811e984f8m, createdTime=Sat Feb 26 13:02:50 CST 2022, time=2022-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1187896, encodeId=f392118e8961f, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤微环境 经验分享：我只能说这是一个接地气的杂志。相比较Nature Medicine, Cancer discovery, Cancer Cell等几个大多数人可望不可及的高端杂志而言。工作创新性一般并且工作量足够的话，Molecular Cancer是比较好的选择。给广大平庸的工作者提供了一个出口。相信以后也会成为Nature Medicine, Cancer discovery, Cancer Cell拒稿论文的备选杂志。至于说非编码环状RNA研究，确实跟风太厉害。真正有价值的不知道有多少。但是非编码确实有存在的重要意义。中科院的陈玲玲研究员就是专门做非编码，顶刊发了不少。中科院院士陈润生也是研究非编码RNA的。国自然也有众多非编码立项。只能说具体论文具体分析。大家擦亮眼睛。看看哪些CircRNA是沙子，哪些是黄金。做好自己的研究，把好自己论文的关。形成良性循环。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a3ed5633363, createdName=ms4000001729535049, createdTime=Tue Jan 25 06:35:02 CST 2022, time=2022-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=902691, encodeId=7f0990269109, content=editor assigned 两周了，还没动静！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=120, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c1c1677649, createdName=littleb, createdTime=Fri Nov 27 09:01:48 CST 2020, time=2020-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2183036, encodeId=e8f421830362e, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：投了一篇大综述，被nature cancer 拒下来的，审稿两个月给了小修, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad038147437, createdName=ms9000001581615796, createdTime=Sun Jan 21 19:51:36 CST 2024, time=2024-01-21, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2089546, encodeId=46a6208954658, content=偏重的研究方向：肿瘤;血管新生 经验分享：投稿三天，一直是editor appointed, 这个状态会持续多久呢，下一步会是什么🤔, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=172, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=af6a5287300, createdName=14856b50m82暂无昵称, createdTime=Wed Sep 21 14:58:39 CST 2022, time=2022-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2089863, encodeId=957d208986326, content=2天被拒, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f7f8116510, createdName=ms8000001299482728, createdTime=Thu Sep 22 23:55:42 CST 2022, time=2022-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813045, encodeId=51cc813045c7, content=明年能破20嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=138, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83er8t83BVhnMma2FlQbSibEIib2ESybuKEkLoRGMJUDXA68kp9iaicHOmWn7SjTx7hKcgqweO5VMahVLyQ/132, createdBy=8a1c2488674, createdName=franzjosef, createdTime=Tue Aug 25 15:07:36 CST 2020, time=2020-08-25, status=1, ipAttribution=)]

2021-03-17 Dr.Yuki

50天了，
还没外审，
Editor Invited 和 Editor assigned切换了三轮，
是没有编辑在工作吗？
太慢了！！

78 5

展开5条回复

[GetPortalCommentsPageByObjectIdResponse(id=1235519, encodeId=bd0712355198b, content=偏重的研究方向：肿瘤生物学 经验分享：这个杂志还能投吗，这个杂志申基金有用吗。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=02dc5450639, createdName=ms4000000217931705, createdTime=Fri Jul 29 18:09:48 CST 2022, time=2022-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=948961, encodeId=d42d948961b7, content=50天了， 还没外审， Editor Invited 和 Editor assigned切换了三轮， 是没有编辑在工作吗？ 太慢了！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKfLDy7CohNq1oaBp12SkJfcXibVV6T5p8zzicUBYPq49OibwhzZswbxnxiaZWSn5QnBGZE64UPzcE1ng/132, createdBy=f10c1934056, createdName=Dr.Yuki, createdTime=Wed Mar 17 11:47:52 CST 2021, time=2021-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1210365, encodeId=433c1210365b7, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：caner 经验分享：最新发表的这两篇国人的综述挺不错的。一篇PROTAC。一篇CRISPR。Molecular Cancer靠综述拉动****无可厚非。一直不明白为啥要以国人论文百分比来评价一个期刊。愚蠢短浅自恨。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a3ed5633363, createdName=ms4000001729535049, createdTime=Mon Apr 11 20:32:55 CST 2022, time=2022-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1197474, encodeId=3f30119e474f1, content=偏重的研究方向：肿瘤 经验分享：molecular cancer杂志近年来尤其热门，深受国人喜爱。但一个杂志受广泛认可需要时间的沉淀，除了坚持发表高质量的论文外，还需要正确对待过去。许多pubpeer等上被揭露的发表在该杂志上的文章，不仅没有撤稿，而且连个订正都没有。在这点是，JECCR杂志就做的相对好点。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77772040306, createdName=1811e984f8m, createdTime=Sat Feb 26 13:02:50 CST 2022, time=2022-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1187896, encodeId=f392118e8961f, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤微环境 经验分享：我只能说这是一个接地气的杂志。相比较Nature Medicine, Cancer discovery, Cancer Cell等几个大多数人可望不可及的高端杂志而言。工作创新性一般并且工作量足够的话，Molecular Cancer是比较好的选择。给广大平庸的工作者提供了一个出口。相信以后也会成为Nature Medicine, Cancer discovery, Cancer Cell拒稿论文的备选杂志。至于说非编码环状RNA研究，确实跟风太厉害。真正有价值的不知道有多少。但是非编码确实有存在的重要意义。中科院的陈玲玲研究员就是专门做非编码，顶刊发了不少。中科院院士陈润生也是研究非编码RNA的。国自然也有众多非编码立项。只能说具体论文具体分析。大家擦亮眼睛。看看哪些CircRNA是沙子，哪些是黄金。做好自己的研究，把好自己论文的关。形成良性循环。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a3ed5633363, createdName=ms4000001729535049, createdTime=Tue Jan 25 06:35:02 CST 2022, time=2022-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=902691, encodeId=7f0990269109, content=editor assigned 两周了，还没动静！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=120, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c1c1677649, createdName=littleb, createdTime=Fri Nov 27 09:01:48 CST 2020, time=2020-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2183036, encodeId=e8f421830362e, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：投了一篇大综述，被nature cancer 拒下来的，审稿两个月给了小修, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad038147437, createdName=ms9000001581615796, createdTime=Sun Jan 21 19:51:36 CST 2024, time=2024-01-21, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2089546, encodeId=46a6208954658, content=偏重的研究方向：肿瘤;血管新生 经验分享：投稿三天，一直是editor appointed, 这个状态会持续多久呢，下一步会是什么🤔, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=172, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=af6a5287300, createdName=14856b50m82暂无昵称, createdTime=Wed Sep 21 14:58:39 CST 2022, time=2022-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2089863, encodeId=957d208986326, content=2天被拒, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f7f8116510, createdName=ms8000001299482728, createdTime=Thu Sep 22 23:55:42 CST 2022, time=2022-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813045, encodeId=51cc813045c7, content=明年能破20嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=138, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83er8t83BVhnMma2FlQbSibEIib2ESybuKEkLoRGMJUDXA68kp9iaicHOmWn7SjTx7hKcgqweO5VMahVLyQ/132, createdBy=8a1c2488674, createdName=franzjosef, createdTime=Tue Aug 25 15:07:36 CST 2020, time=2020-08-25, status=1, ipAttribution=)]

2022-04-11 ms4000001729535049

审稿速度:6.0 | 投稿命中率:50.0
偏重的研究方向：caner
经验分享：最新发表的这两篇国人的综述挺不错的。一篇PROTAC。一篇CRISPR。Molecular Cancer靠综述拉动****无可厚非。一直不明白为啥要以国人论文百分比来评价一个期刊。愚蠢短浅自恨。

66 5

展开5条回复

[GetPortalCommentsPageByObjectIdResponse(id=1235519, encodeId=bd0712355198b, content=偏重的研究方向：肿瘤生物学 经验分享：这个杂志还能投吗，这个杂志申基金有用吗。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=02dc5450639, createdName=ms4000000217931705, createdTime=Fri Jul 29 18:09:48 CST 2022, time=2022-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=948961, encodeId=d42d948961b7, content=50天了， 还没外审， Editor Invited 和 Editor assigned切换了三轮， 是没有编辑在工作吗？ 太慢了！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKfLDy7CohNq1oaBp12SkJfcXibVV6T5p8zzicUBYPq49OibwhzZswbxnxiaZWSn5QnBGZE64UPzcE1ng/132, createdBy=f10c1934056, createdName=Dr.Yuki, createdTime=Wed Mar 17 11:47:52 CST 2021, time=2021-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1210365, encodeId=433c1210365b7, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：caner 经验分享：最新发表的这两篇国人的综述挺不错的。一篇PROTAC。一篇CRISPR。Molecular Cancer靠综述拉动****无可厚非。一直不明白为啥要以国人论文百分比来评价一个期刊。愚蠢短浅自恨。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a3ed5633363, createdName=ms4000001729535049, createdTime=Mon Apr 11 20:32:55 CST 2022, time=2022-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1197474, encodeId=3f30119e474f1, content=偏重的研究方向：肿瘤 经验分享：molecular cancer杂志近年来尤其热门，深受国人喜爱。但一个杂志受广泛认可需要时间的沉淀，除了坚持发表高质量的论文外，还需要正确对待过去。许多pubpeer等上被揭露的发表在该杂志上的文章，不仅没有撤稿，而且连个订正都没有。在这点是，JECCR杂志就做的相对好点。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77772040306, createdName=1811e984f8m, createdTime=Sat Feb 26 13:02:50 CST 2022, time=2022-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1187896, encodeId=f392118e8961f, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤微环境 经验分享：我只能说这是一个接地气的杂志。相比较Nature Medicine, Cancer discovery, Cancer Cell等几个大多数人可望不可及的高端杂志而言。工作创新性一般并且工作量足够的话，Molecular Cancer是比较好的选择。给广大平庸的工作者提供了一个出口。相信以后也会成为Nature Medicine, Cancer discovery, Cancer Cell拒稿论文的备选杂志。至于说非编码环状RNA研究，确实跟风太厉害。真正有价值的不知道有多少。但是非编码确实有存在的重要意义。中科院的陈玲玲研究员就是专门做非编码，顶刊发了不少。中科院院士陈润生也是研究非编码RNA的。国自然也有众多非编码立项。只能说具体论文具体分析。大家擦亮眼睛。看看哪些CircRNA是沙子，哪些是黄金。做好自己的研究，把好自己论文的关。形成良性循环。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a3ed5633363, createdName=ms4000001729535049, createdTime=Tue Jan 25 06:35:02 CST 2022, time=2022-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=902691, encodeId=7f0990269109, content=editor assigned 两周了，还没动静！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=120, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c1c1677649, createdName=littleb, createdTime=Fri Nov 27 09:01:48 CST 2020, time=2020-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2183036, encodeId=e8f421830362e, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：投了一篇大综述，被nature cancer 拒下来的，审稿两个月给了小修, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad038147437, createdName=ms9000001581615796, createdTime=Sun Jan 21 19:51:36 CST 2024, time=2024-01-21, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2089546, encodeId=46a6208954658, content=偏重的研究方向：肿瘤;血管新生 经验分享：投稿三天，一直是editor appointed, 这个状态会持续多久呢，下一步会是什么🤔, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=172, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=af6a5287300, createdName=14856b50m82暂无昵称, createdTime=Wed Sep 21 14:58:39 CST 2022, time=2022-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2089863, encodeId=957d208986326, content=2天被拒, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f7f8116510, createdName=ms8000001299482728, createdTime=Thu Sep 22 23:55:42 CST 2022, time=2022-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813045, encodeId=51cc813045c7, content=明年能破20嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=138, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83er8t83BVhnMma2FlQbSibEIib2ESybuKEkLoRGMJUDXA68kp9iaicHOmWn7SjTx7hKcgqweO5VMahVLyQ/132, createdBy=8a1c2488674, createdName=franzjosef, createdTime=Tue Aug 25 15:07:36 CST 2020, time=2020-08-25, status=1, ipAttribution=)]

2022-02-26 1811e984f8m

偏重的研究方向：肿瘤
经验分享：molecular cancer杂志近年来尤其热门，深受国人喜爱。但一个杂志受广泛认可需要时间的沉淀，除了坚持发表高质量的论文外，还需要正确对待过去。许多pubpeer等上被揭露的发表在该杂志上的文章，不仅没有撤稿，而且连个订正都没有。在这点是，JECCR杂志就做的相对好点。

37 5

展开5条回复

[GetPortalCommentsPageByObjectIdResponse(id=1235519, encodeId=bd0712355198b, content=偏重的研究方向：肿瘤生物学 经验分享：这个杂志还能投吗，这个杂志申基金有用吗。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=02dc5450639, createdName=ms4000000217931705, createdTime=Fri Jul 29 18:09:48 CST 2022, time=2022-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=948961, encodeId=d42d948961b7, content=50天了， 还没外审， Editor Invited 和 Editor assigned切换了三轮， 是没有编辑在工作吗？ 太慢了！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKfLDy7CohNq1oaBp12SkJfcXibVV6T5p8zzicUBYPq49OibwhzZswbxnxiaZWSn5QnBGZE64UPzcE1ng/132, createdBy=f10c1934056, createdName=Dr.Yuki, createdTime=Wed Mar 17 11:47:52 CST 2021, time=2021-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1210365, encodeId=433c1210365b7, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：caner 经验分享：最新发表的这两篇国人的综述挺不错的。一篇PROTAC。一篇CRISPR。Molecular Cancer靠综述拉动****无可厚非。一直不明白为啥要以国人论文百分比来评价一个期刊。愚蠢短浅自恨。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a3ed5633363, createdName=ms4000001729535049, createdTime=Mon Apr 11 20:32:55 CST 2022, time=2022-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1197474, encodeId=3f30119e474f1, content=偏重的研究方向：肿瘤 经验分享：molecular cancer杂志近年来尤其热门，深受国人喜爱。但一个杂志受广泛认可需要时间的沉淀，除了坚持发表高质量的论文外，还需要正确对待过去。许多pubpeer等上被揭露的发表在该杂志上的文章，不仅没有撤稿，而且连个订正都没有。在这点是，JECCR杂志就做的相对好点。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77772040306, createdName=1811e984f8m, createdTime=Sat Feb 26 13:02:50 CST 2022, time=2022-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1187896, encodeId=f392118e8961f, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤微环境 经验分享：我只能说这是一个接地气的杂志。相比较Nature Medicine, Cancer discovery, Cancer Cell等几个大多数人可望不可及的高端杂志而言。工作创新性一般并且工作量足够的话，Molecular Cancer是比较好的选择。给广大平庸的工作者提供了一个出口。相信以后也会成为Nature Medicine, Cancer discovery, Cancer Cell拒稿论文的备选杂志。至于说非编码环状RNA研究，确实跟风太厉害。真正有价值的不知道有多少。但是非编码确实有存在的重要意义。中科院的陈玲玲研究员就是专门做非编码，顶刊发了不少。中科院院士陈润生也是研究非编码RNA的。国自然也有众多非编码立项。只能说具体论文具体分析。大家擦亮眼睛。看看哪些CircRNA是沙子，哪些是黄金。做好自己的研究，把好自己论文的关。形成良性循环。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a3ed5633363, createdName=ms4000001729535049, createdTime=Tue Jan 25 06:35:02 CST 2022, time=2022-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=902691, encodeId=7f0990269109, content=editor assigned 两周了，还没动静！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=120, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c1c1677649, createdName=littleb, createdTime=Fri Nov 27 09:01:48 CST 2020, time=2020-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2183036, encodeId=e8f421830362e, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：投了一篇大综述，被nature cancer 拒下来的，审稿两个月给了小修, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad038147437, createdName=ms9000001581615796, createdTime=Sun Jan 21 19:51:36 CST 2024, time=2024-01-21, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2089546, encodeId=46a6208954658, content=偏重的研究方向：肿瘤;血管新生 经验分享：投稿三天，一直是editor appointed, 这个状态会持续多久呢，下一步会是什么🤔, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=172, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=af6a5287300, createdName=14856b50m82暂无昵称, createdTime=Wed Sep 21 14:58:39 CST 2022, time=2022-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2089863, encodeId=957d208986326, content=2天被拒, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f7f8116510, createdName=ms8000001299482728, createdTime=Thu Sep 22 23:55:42 CST 2022, time=2022-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813045, encodeId=51cc813045c7, content=明年能破20嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=138, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83er8t83BVhnMma2FlQbSibEIib2ESybuKEkLoRGMJUDXA68kp9iaicHOmWn7SjTx7hKcgqweO5VMahVLyQ/132, createdBy=8a1c2488674, createdName=franzjosef, createdTime=Tue Aug 25 15:07:36 CST 2020, time=2020-08-25, status=1, ipAttribution=)]

2022-01-25 ms4000001729535049

审稿速度:6.0 | 投稿命中率:50.0
偏重的研究方向：肿瘤微环境
经验分享：我只能说这是一个接地气的杂志。相比较Nature Medicine, Cancer discovery, Cancer Cell等几个大多数人可望不可及的高端杂志而言。工作创新性一般并且工作量足够的话，Molecular Cancer是比较好的选择。给广大平庸的工作者提供了一个出口。相信以后也会成为Nature Medicine, Cancer discovery, Cancer Cell拒稿论文的备选杂志。至于说非编码环状RNA研究，确实跟风太厉害。真正有价值的不知道有多少。但是非编码确实有存在的重要意义。中科院的陈玲玲研究员就是专门做非编码，顶刊发了不少。中科院院士陈润生也是研究非编码RNA的。国自然也有众多非编码立项。只能说具体论文具体分析。大家擦亮眼睛。看看哪些CircRNA是沙子，哪些是黄金。做好自己的研究，把好自己论文的关。形成良性循环。

40 5

展开5条回复

[GetPortalCommentsPageByObjectIdResponse(id=1235519, encodeId=bd0712355198b, content=偏重的研究方向：肿瘤生物学 经验分享：这个杂志还能投吗，这个杂志申基金有用吗。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=02dc5450639, createdName=ms4000000217931705, createdTime=Fri Jul 29 18:09:48 CST 2022, time=2022-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=948961, encodeId=d42d948961b7, content=50天了， 还没外审， Editor Invited 和 Editor assigned切换了三轮， 是没有编辑在工作吗？ 太慢了！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKfLDy7CohNq1oaBp12SkJfcXibVV6T5p8zzicUBYPq49OibwhzZswbxnxiaZWSn5QnBGZE64UPzcE1ng/132, createdBy=f10c1934056, createdName=Dr.Yuki, createdTime=Wed Mar 17 11:47:52 CST 2021, time=2021-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1210365, encodeId=433c1210365b7, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：caner 经验分享：最新发表的这两篇国人的综述挺不错的。一篇PROTAC。一篇CRISPR。Molecular Cancer靠综述拉动****无可厚非。一直不明白为啥要以国人论文百分比来评价一个期刊。愚蠢短浅自恨。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a3ed5633363, createdName=ms4000001729535049, createdTime=Mon Apr 11 20:32:55 CST 2022, time=2022-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1197474, encodeId=3f30119e474f1, content=偏重的研究方向：肿瘤 经验分享：molecular cancer杂志近年来尤其热门，深受国人喜爱。但一个杂志受广泛认可需要时间的沉淀，除了坚持发表高质量的论文外，还需要正确对待过去。许多pubpeer等上被揭露的发表在该杂志上的文章，不仅没有撤稿，而且连个订正都没有。在这点是，JECCR杂志就做的相对好点。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77772040306, createdName=1811e984f8m, createdTime=Sat Feb 26 13:02:50 CST 2022, time=2022-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1187896, encodeId=f392118e8961f, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤微环境 经验分享：我只能说这是一个接地气的杂志。相比较Nature Medicine, Cancer discovery, Cancer Cell等几个大多数人可望不可及的高端杂志而言。工作创新性一般并且工作量足够的话，Molecular Cancer是比较好的选择。给广大平庸的工作者提供了一个出口。相信以后也会成为Nature Medicine, Cancer discovery, Cancer Cell拒稿论文的备选杂志。至于说非编码环状RNA研究，确实跟风太厉害。真正有价值的不知道有多少。但是非编码确实有存在的重要意义。中科院的陈玲玲研究员就是专门做非编码，顶刊发了不少。中科院院士陈润生也是研究非编码RNA的。国自然也有众多非编码立项。只能说具体论文具体分析。大家擦亮眼睛。看看哪些CircRNA是沙子，哪些是黄金。做好自己的研究，把好自己论文的关。形成良性循环。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a3ed5633363, createdName=ms4000001729535049, createdTime=Tue Jan 25 06:35:02 CST 2022, time=2022-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=902691, encodeId=7f0990269109, content=editor assigned 两周了，还没动静！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=120, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c1c1677649, createdName=littleb, createdTime=Fri Nov 27 09:01:48 CST 2020, time=2020-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2183036, encodeId=e8f421830362e, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：投了一篇大综述，被nature cancer 拒下来的，审稿两个月给了小修, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad038147437, createdName=ms9000001581615796, createdTime=Sun Jan 21 19:51:36 CST 2024, time=2024-01-21, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2089546, encodeId=46a6208954658, content=偏重的研究方向：肿瘤;血管新生 经验分享：投稿三天，一直是editor appointed, 这个状态会持续多久呢，下一步会是什么🤔, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=172, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=af6a5287300, createdName=14856b50m82暂无昵称, createdTime=Wed Sep 21 14:58:39 CST 2022, time=2022-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2089863, encodeId=957d208986326, content=2天被拒, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f7f8116510, createdName=ms8000001299482728, createdTime=Thu Sep 22 23:55:42 CST 2022, time=2022-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813045, encodeId=51cc813045c7, content=明年能破20嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=138, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83er8t83BVhnMma2FlQbSibEIib2ESybuKEkLoRGMJUDXA68kp9iaicHOmWn7SjTx7hKcgqweO5VMahVLyQ/132, createdBy=8a1c2488674, createdName=franzjosef, createdTime=Tue Aug 25 15:07:36 CST 2020, time=2020-08-25, status=1, ipAttribution=)]

2020-11-27 littleb

editor assigned 两周了，还没动静！

120 5

展开5条回复

[GetPortalCommentsPageByObjectIdResponse(id=1235519, encodeId=bd0712355198b, content=偏重的研究方向：肿瘤生物学 经验分享：这个杂志还能投吗，这个杂志申基金有用吗。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=02dc5450639, createdName=ms4000000217931705, createdTime=Fri Jul 29 18:09:48 CST 2022, time=2022-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=948961, encodeId=d42d948961b7, content=50天了， 还没外审， Editor Invited 和 Editor assigned切换了三轮， 是没有编辑在工作吗？ 太慢了！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKfLDy7CohNq1oaBp12SkJfcXibVV6T5p8zzicUBYPq49OibwhzZswbxnxiaZWSn5QnBGZE64UPzcE1ng/132, createdBy=f10c1934056, createdName=Dr.Yuki, createdTime=Wed Mar 17 11:47:52 CST 2021, time=2021-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1210365, encodeId=433c1210365b7, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：caner 经验分享：最新发表的这两篇国人的综述挺不错的。一篇PROTAC。一篇CRISPR。Molecular Cancer靠综述拉动****无可厚非。一直不明白为啥要以国人论文百分比来评价一个期刊。愚蠢短浅自恨。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a3ed5633363, createdName=ms4000001729535049, createdTime=Mon Apr 11 20:32:55 CST 2022, time=2022-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1197474, encodeId=3f30119e474f1, content=偏重的研究方向：肿瘤 经验分享：molecular cancer杂志近年来尤其热门，深受国人喜爱。但一个杂志受广泛认可需要时间的沉淀，除了坚持发表高质量的论文外，还需要正确对待过去。许多pubpeer等上被揭露的发表在该杂志上的文章，不仅没有撤稿，而且连个订正都没有。在这点是，JECCR杂志就做的相对好点。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77772040306, createdName=1811e984f8m, createdTime=Sat Feb 26 13:02:50 CST 2022, time=2022-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1187896, encodeId=f392118e8961f, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤微环境 经验分享：我只能说这是一个接地气的杂志。相比较Nature Medicine, Cancer discovery, Cancer Cell等几个大多数人可望不可及的高端杂志而言。工作创新性一般并且工作量足够的话，Molecular Cancer是比较好的选择。给广大平庸的工作者提供了一个出口。相信以后也会成为Nature Medicine, Cancer discovery, Cancer Cell拒稿论文的备选杂志。至于说非编码环状RNA研究，确实跟风太厉害。真正有价值的不知道有多少。但是非编码确实有存在的重要意义。中科院的陈玲玲研究员就是专门做非编码，顶刊发了不少。中科院院士陈润生也是研究非编码RNA的。国自然也有众多非编码立项。只能说具体论文具体分析。大家擦亮眼睛。看看哪些CircRNA是沙子，哪些是黄金。做好自己的研究，把好自己论文的关。形成良性循环。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a3ed5633363, createdName=ms4000001729535049, createdTime=Tue Jan 25 06:35:02 CST 2022, time=2022-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=902691, encodeId=7f0990269109, content=editor assigned 两周了，还没动静！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=120, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c1c1677649, createdName=littleb, createdTime=Fri Nov 27 09:01:48 CST 2020, time=2020-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2183036, encodeId=e8f421830362e, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：投了一篇大综述，被nature cancer 拒下来的，审稿两个月给了小修, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad038147437, createdName=ms9000001581615796, createdTime=Sun Jan 21 19:51:36 CST 2024, time=2024-01-21, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2089546, encodeId=46a6208954658, content=偏重的研究方向：肿瘤;血管新生 经验分享：投稿三天，一直是editor appointed, 这个状态会持续多久呢，下一步会是什么🤔, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=172, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=af6a5287300, createdName=14856b50m82暂无昵称, createdTime=Wed Sep 21 14:58:39 CST 2022, time=2022-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2089863, encodeId=957d208986326, content=2天被拒, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f7f8116510, createdName=ms8000001299482728, createdTime=Thu Sep 22 23:55:42 CST 2022, time=2022-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813045, encodeId=51cc813045c7, content=明年能破20嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=138, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83er8t83BVhnMma2FlQbSibEIib2ESybuKEkLoRGMJUDXA68kp9iaicHOmWn7SjTx7hKcgqweO5VMahVLyQ/132, createdBy=8a1c2488674, createdName=franzjosef, createdTime=Tue Aug 25 15:07:36 CST 2020, time=2020-08-25, status=1, ipAttribution=)]

2024-01-21 ms9000001581615796 来自江苏省

审稿速度:2.0 | 投稿命中率:25.0
经验分享：投了一篇大综述，被nature cancer 拒下来的，审稿两个月给了小修

36 4

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=1235519, encodeId=bd0712355198b, content=偏重的研究方向：肿瘤生物学 经验分享：这个杂志还能投吗，这个杂志申基金有用吗。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=02dc5450639, createdName=ms4000000217931705, createdTime=Fri Jul 29 18:09:48 CST 2022, time=2022-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=948961, encodeId=d42d948961b7, content=50天了， 还没外审， Editor Invited 和 Editor assigned切换了三轮， 是没有编辑在工作吗？ 太慢了！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKfLDy7CohNq1oaBp12SkJfcXibVV6T5p8zzicUBYPq49OibwhzZswbxnxiaZWSn5QnBGZE64UPzcE1ng/132, createdBy=f10c1934056, createdName=Dr.Yuki, createdTime=Wed Mar 17 11:47:52 CST 2021, time=2021-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1210365, encodeId=433c1210365b7, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：caner 经验分享：最新发表的这两篇国人的综述挺不错的。一篇PROTAC。一篇CRISPR。Molecular Cancer靠综述拉动****无可厚非。一直不明白为啥要以国人论文百分比来评价一个期刊。愚蠢短浅自恨。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a3ed5633363, createdName=ms4000001729535049, createdTime=Mon Apr 11 20:32:55 CST 2022, time=2022-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1197474, encodeId=3f30119e474f1, content=偏重的研究方向：肿瘤 经验分享：molecular cancer杂志近年来尤其热门，深受国人喜爱。但一个杂志受广泛认可需要时间的沉淀，除了坚持发表高质量的论文外，还需要正确对待过去。许多pubpeer等上被揭露的发表在该杂志上的文章，不仅没有撤稿，而且连个订正都没有。在这点是，JECCR杂志就做的相对好点。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77772040306, createdName=1811e984f8m, createdTime=Sat Feb 26 13:02:50 CST 2022, time=2022-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1187896, encodeId=f392118e8961f, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤微环境 经验分享：我只能说这是一个接地气的杂志。相比较Nature Medicine, Cancer discovery, Cancer Cell等几个大多数人可望不可及的高端杂志而言。工作创新性一般并且工作量足够的话，Molecular Cancer是比较好的选择。给广大平庸的工作者提供了一个出口。相信以后也会成为Nature Medicine, Cancer discovery, Cancer Cell拒稿论文的备选杂志。至于说非编码环状RNA研究，确实跟风太厉害。真正有价值的不知道有多少。但是非编码确实有存在的重要意义。中科院的陈玲玲研究员就是专门做非编码，顶刊发了不少。中科院院士陈润生也是研究非编码RNA的。国自然也有众多非编码立项。只能说具体论文具体分析。大家擦亮眼睛。看看哪些CircRNA是沙子，哪些是黄金。做好自己的研究，把好自己论文的关。形成良性循环。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a3ed5633363, createdName=ms4000001729535049, createdTime=Tue Jan 25 06:35:02 CST 2022, time=2022-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=902691, encodeId=7f0990269109, content=editor assigned 两周了，还没动静！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=120, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c1c1677649, createdName=littleb, createdTime=Fri Nov 27 09:01:48 CST 2020, time=2020-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2183036, encodeId=e8f421830362e, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：投了一篇大综述，被nature cancer 拒下来的，审稿两个月给了小修, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad038147437, createdName=ms9000001581615796, createdTime=Sun Jan 21 19:51:36 CST 2024, time=2024-01-21, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2089546, encodeId=46a6208954658, content=偏重的研究方向：肿瘤;血管新生 经验分享：投稿三天，一直是editor appointed, 这个状态会持续多久呢，下一步会是什么🤔, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=172, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=af6a5287300, createdName=14856b50m82暂无昵称, createdTime=Wed Sep 21 14:58:39 CST 2022, time=2022-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2089863, encodeId=957d208986326, content=2天被拒, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f7f8116510, createdName=ms8000001299482728, createdTime=Thu Sep 22 23:55:42 CST 2022, time=2022-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813045, encodeId=51cc813045c7, content=明年能破20嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=138, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83er8t83BVhnMma2FlQbSibEIib2ESybuKEkLoRGMJUDXA68kp9iaicHOmWn7SjTx7hKcgqweO5VMahVLyQ/132, createdBy=8a1c2488674, createdName=franzjosef, createdTime=Tue Aug 25 15:07:36 CST 2020, time=2020-08-25, status=1, ipAttribution=)]

2022-09-21 14856b50m82暂无昵称

偏重的研究方向：肿瘤;血管新生
经验分享：投稿三天，一直是editor appointed, 这个状态会持续多久呢，下一步会是什么🤔

172 4

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=1235519, encodeId=bd0712355198b, content=偏重的研究方向：肿瘤生物学 经验分享：这个杂志还能投吗，这个杂志申基金有用吗。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=02dc5450639, createdName=ms4000000217931705, createdTime=Fri Jul 29 18:09:48 CST 2022, time=2022-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=948961, encodeId=d42d948961b7, content=50天了， 还没外审， Editor Invited 和 Editor assigned切换了三轮， 是没有编辑在工作吗？ 太慢了！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKfLDy7CohNq1oaBp12SkJfcXibVV6T5p8zzicUBYPq49OibwhzZswbxnxiaZWSn5QnBGZE64UPzcE1ng/132, createdBy=f10c1934056, createdName=Dr.Yuki, createdTime=Wed Mar 17 11:47:52 CST 2021, time=2021-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1210365, encodeId=433c1210365b7, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：caner 经验分享：最新发表的这两篇国人的综述挺不错的。一篇PROTAC。一篇CRISPR。Molecular Cancer靠综述拉动****无可厚非。一直不明白为啥要以国人论文百分比来评价一个期刊。愚蠢短浅自恨。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a3ed5633363, createdName=ms4000001729535049, createdTime=Mon Apr 11 20:32:55 CST 2022, time=2022-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1197474, encodeId=3f30119e474f1, content=偏重的研究方向：肿瘤 经验分享：molecular cancer杂志近年来尤其热门，深受国人喜爱。但一个杂志受广泛认可需要时间的沉淀，除了坚持发表高质量的论文外，还需要正确对待过去。许多pubpeer等上被揭露的发表在该杂志上的文章，不仅没有撤稿，而且连个订正都没有。在这点是，JECCR杂志就做的相对好点。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77772040306, createdName=1811e984f8m, createdTime=Sat Feb 26 13:02:50 CST 2022, time=2022-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1187896, encodeId=f392118e8961f, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤微环境 经验分享：我只能说这是一个接地气的杂志。相比较Nature Medicine, Cancer discovery, Cancer Cell等几个大多数人可望不可及的高端杂志而言。工作创新性一般并且工作量足够的话，Molecular Cancer是比较好的选择。给广大平庸的工作者提供了一个出口。相信以后也会成为Nature Medicine, Cancer discovery, Cancer Cell拒稿论文的备选杂志。至于说非编码环状RNA研究，确实跟风太厉害。真正有价值的不知道有多少。但是非编码确实有存在的重要意义。中科院的陈玲玲研究员就是专门做非编码，顶刊发了不少。中科院院士陈润生也是研究非编码RNA的。国自然也有众多非编码立项。只能说具体论文具体分析。大家擦亮眼睛。看看哪些CircRNA是沙子，哪些是黄金。做好自己的研究，把好自己论文的关。形成良性循环。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a3ed5633363, createdName=ms4000001729535049, createdTime=Tue Jan 25 06:35:02 CST 2022, time=2022-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=902691, encodeId=7f0990269109, content=editor assigned 两周了，还没动静！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=120, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c1c1677649, createdName=littleb, createdTime=Fri Nov 27 09:01:48 CST 2020, time=2020-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2183036, encodeId=e8f421830362e, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：投了一篇大综述，被nature cancer 拒下来的，审稿两个月给了小修, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad038147437, createdName=ms9000001581615796, createdTime=Sun Jan 21 19:51:36 CST 2024, time=2024-01-21, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2089546, encodeId=46a6208954658, content=偏重的研究方向：肿瘤;血管新生 经验分享：投稿三天，一直是editor appointed, 这个状态会持续多久呢，下一步会是什么🤔, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=172, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=af6a5287300, createdName=14856b50m82暂无昵称, createdTime=Wed Sep 21 14:58:39 CST 2022, time=2022-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2089863, encodeId=957d208986326, content=2天被拒, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f7f8116510, createdName=ms8000001299482728, createdTime=Thu Sep 22 23:55:42 CST 2022, time=2022-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813045, encodeId=51cc813045c7, content=明年能破20嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=138, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83er8t83BVhnMma2FlQbSibEIib2ESybuKEkLoRGMJUDXA68kp9iaicHOmWn7SjTx7hKcgqweO5VMahVLyQ/132, createdBy=8a1c2488674, createdName=franzjosef, createdTime=Tue Aug 25 15:07:36 CST 2020, time=2020-08-25, status=1, ipAttribution=)]

2022-09-22 ms8000001299482728

2天被拒

58 4

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=1235519, encodeId=bd0712355198b, content=偏重的研究方向：肿瘤生物学 经验分享：这个杂志还能投吗，这个杂志申基金有用吗。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=02dc5450639, createdName=ms4000000217931705, createdTime=Fri Jul 29 18:09:48 CST 2022, time=2022-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=948961, encodeId=d42d948961b7, content=50天了， 还没外审， Editor Invited 和 Editor assigned切换了三轮， 是没有编辑在工作吗？ 太慢了！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKfLDy7CohNq1oaBp12SkJfcXibVV6T5p8zzicUBYPq49OibwhzZswbxnxiaZWSn5QnBGZE64UPzcE1ng/132, createdBy=f10c1934056, createdName=Dr.Yuki, createdTime=Wed Mar 17 11:47:52 CST 2021, time=2021-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1210365, encodeId=433c1210365b7, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：caner 经验分享：最新发表的这两篇国人的综述挺不错的。一篇PROTAC。一篇CRISPR。Molecular Cancer靠综述拉动****无可厚非。一直不明白为啥要以国人论文百分比来评价一个期刊。愚蠢短浅自恨。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a3ed5633363, createdName=ms4000001729535049, createdTime=Mon Apr 11 20:32:55 CST 2022, time=2022-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1197474, encodeId=3f30119e474f1, content=偏重的研究方向：肿瘤 经验分享：molecular cancer杂志近年来尤其热门，深受国人喜爱。但一个杂志受广泛认可需要时间的沉淀，除了坚持发表高质量的论文外，还需要正确对待过去。许多pubpeer等上被揭露的发表在该杂志上的文章，不仅没有撤稿，而且连个订正都没有。在这点是，JECCR杂志就做的相对好点。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77772040306, createdName=1811e984f8m, createdTime=Sat Feb 26 13:02:50 CST 2022, time=2022-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1187896, encodeId=f392118e8961f, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤微环境 经验分享：我只能说这是一个接地气的杂志。相比较Nature Medicine, Cancer discovery, Cancer Cell等几个大多数人可望不可及的高端杂志而言。工作创新性一般并且工作量足够的话，Molecular Cancer是比较好的选择。给广大平庸的工作者提供了一个出口。相信以后也会成为Nature Medicine, Cancer discovery, Cancer Cell拒稿论文的备选杂志。至于说非编码环状RNA研究，确实跟风太厉害。真正有价值的不知道有多少。但是非编码确实有存在的重要意义。中科院的陈玲玲研究员就是专门做非编码，顶刊发了不少。中科院院士陈润生也是研究非编码RNA的。国自然也有众多非编码立项。只能说具体论文具体分析。大家擦亮眼睛。看看哪些CircRNA是沙子，哪些是黄金。做好自己的研究，把好自己论文的关。形成良性循环。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a3ed5633363, createdName=ms4000001729535049, createdTime=Tue Jan 25 06:35:02 CST 2022, time=2022-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=902691, encodeId=7f0990269109, content=editor assigned 两周了，还没动静！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=120, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c1c1677649, createdName=littleb, createdTime=Fri Nov 27 09:01:48 CST 2020, time=2020-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2183036, encodeId=e8f421830362e, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：投了一篇大综述，被nature cancer 拒下来的，审稿两个月给了小修, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad038147437, createdName=ms9000001581615796, createdTime=Sun Jan 21 19:51:36 CST 2024, time=2024-01-21, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2089546, encodeId=46a6208954658, content=偏重的研究方向：肿瘤;血管新生 经验分享：投稿三天，一直是editor appointed, 这个状态会持续多久呢，下一步会是什么🤔, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=172, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=af6a5287300, createdName=14856b50m82暂无昵称, createdTime=Wed Sep 21 14:58:39 CST 2022, time=2022-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2089863, encodeId=957d208986326, content=2天被拒, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f7f8116510, createdName=ms8000001299482728, createdTime=Thu Sep 22 23:55:42 CST 2022, time=2022-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813045, encodeId=51cc813045c7, content=明年能破20嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=138, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83er8t83BVhnMma2FlQbSibEIib2ESybuKEkLoRGMJUDXA68kp9iaicHOmWn7SjTx7hKcgqweO5VMahVLyQ/132, createdBy=8a1c2488674, createdName=franzjosef, createdTime=Tue Aug 25 15:07:36 CST 2020, time=2020-08-25, status=1, ipAttribution=)]

2020-08-25 franzjosef

明年能破20嘛

138 4

展开4条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务